Early Cellular Responses of Prostate Carcinoma Cells to Sepantronium Bromide (YM155) Involve Suppression of mTORC1 by AMPK

The imidazolium compound YM155, first discovered as a potent inhibitor of Survivin, effectively kills many carcinomas in preclinical models. However, the upstream signaling mechanism triggered by YM155 remains unclear. Here we studied early signaling responses in vitro in prostate and renal cancer c...

Celý popis

Uloženo v:
Podrobná bibliografie
Vydáno v:Sci Rep
Hlavní autoři: Danielpour, David, Gao, Zhaofeng, Zmina, Patrick M., Shankar, Eswar, Shultes, Benjamin C., Jobava, Raul, Welford, Scott M., Hatzoglou, Maria
Médium: Artigo
Jazyk:Inglês
Vydáno: Nature Publishing Group UK 2019
Témata:
Article
On-line přístup:https://ncbi.nlm.nih.gov/pmc/articles/PMC6687778/
https://ncbi.nlm.nih.gov/pubmed/31395901
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1038/s41598-019-47573-y
Tagy: Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!

Podobné jednotky